Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
AGTR1 185 SAPRISARTAN POTASSIUM CHEMBL305544 antagonist TdgClinicalTrial, TEND, DrugBank, TTD 11752352, 10579749
AGTR1 185 TASOSARTAN CHEMBL432162 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank, TTD 11046101, 11752352, 11683476, 12113820
AGTR1 185 LEVODOPA CHEMBL1009 NCI 9458818
AGTR1 185 OLMESARTAN CHEMBL1516 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, TTD
AGTR1 185 HYDROCHLOROTHIAZIDE CHEMBL435 PharmGKB
AGTR1 185 MEXILETINE CHEMBL558 antagonist GuideToPharmacologyInteractions
AGTR1 185 AZILSARTAN KAMEDOXOMIL CHEMBL2103795 antagonist ChemblInteractions
AGTR1 185 SARALASIN ACETATE CHEMBL1200670 antagonist ChemblInteractions
AGTR1 185 IRBESARTAN CHEMBL1513 antagonist PharmGKB, TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank, TTD 10069682, 18627212, 15030294, 11752352, 10075381, 14716205, 15101793, 10373224, 17408613, 10082498, 10822210, 11486244, 7843749
AGTR1 185 FORASARTAN CHEMBL315021 antagonist TdgClinicalTrial, TEND, DrugBank, TTD 11752352, 11569611, 9156352, 8981065
AGTR1 185 ATORVASTATIN CHEMBL1487 NCI 11179461
AGTR1 185 STANOLONE CHEMBL27769 NCI 16482568, 16990489
AGTR1 185 GENISTEIN CHEMBL44 NCI 7476882
AGTR1 185 IDOXIFENE CHEMBL6318 NCI 11588112
AGTR1 185 OLMESARTAN MEDOXOMIL CHEMBL1200692 antagonist ChemblInteractions, TTD
AGTR1 185 SPARSENTAN CHEMBL539423 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
AGTR1 185 ANGIOTENSIN III CHEMBL56448 agonist GuideToPharmacologyInteractions
AGTR1 185 METYRAPONE CHEMBL934 antagonist GuideToPharmacologyInteractions
AGTR1 185 LOSARTAN POTASSIUM CHEMBL995 antagonist ChemblInteractions
AGTR1 185 CANDESARTAN CILEXETIL CHEMBL1014 antagonist ChemblInteractions
AGTR1 185 VALSARTAN CHEMBL1069 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank, TTD 11752352, 8242249, 12460705, 12023686, 8577935, 15579516
AGTR1 185 VOLANESORSEN SODIUM CHEMBL3544989 NCI 10100098
AGTR1 185 LOSARTAN CHEMBL191 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
AGTR1 185 ANGIOTENSIN II CHEMBL408403 agonist GuideToPharmacologyInteractions
AGTR1 185 ANGIOTENSIN IV CHEMBL261120 agonist GuideToPharmacologyInteractions
AGTR1 185 TELMISARTAN CHEMBL1017 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank, TTD 16938288, 15498586, 11408526, 11558835, 11752352, 20448797, 18580862, 11444497, 10067800, 9259062, 19147680, 15617852, 17691961, 9878991
AGTR1 185 EPROSARTAN MESYLATE CHEMBL1200987 antagonist ChemblInteractions, TTD
AGTR1 185 EPROSARTAN CHEMBL813 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, TTD
AGTR1 185 CANDESARTAN CHEMBL1016 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, TTD
AGTR1 185 AZILSARTAN CHEMBL57242 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
AGTR1 185 INDOMETHACIN CHEMBL6 NCI 9357777
AGTR1 185 CHEMBL288174 CHEMBL288174 agonist GuideToPharmacologyInteractions
AGTR1 185 CHEMBL345132 CHEMBL345132 antagonist GuideToPharmacologyInteractions
AGTR1 185 CHEMBL344662 CHEMBL344662 antagonist GuideToPharmacologyInteractions
AGTR1 185 PRATOSARTAN CHEMBL41194 antagonist ChemblInteractions
AGTR1 185 INTERFERON GAMA-1B CHEMBL1201564 NCI 9231818
AGTR1 185 DEXAMETHASONE CHEMBL384467 NCI 16482568
AGTR1 185 ASCORBATE CHEMBL196 NCI 18091746
AGTR1 185 CYCLOSPORINE CHEMBL160 NCI 17477024
AGTR1 185 HYDROGEN PEROXIDE CHEMBL71595 NCI 18006461

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
AGTR1 rs5186 AA atenolol efficacy no No significant differences in the change in diastolic or systolic blood pressure after 3 months of treatment were seen between the genotypes. 43 patients were given atenolol and 43 were given irbesartan; these two drug cohorts were analyzed as separate groups. Genotype AA is not associated with response to atenolol or irbesartan in people with Hypertension as compared to genotypes AC + CC. 11593098 1183615168
AGTR1 rs2640543 GG benazepril efficacy yes Only when rs7079 genotype (AGT gene) is also taken into account (gene-gene interaction model). Please see study for analysis details - the genotype conferring increased likelihood of response/ sensitivity was not clear. Genotype GG is associated with response to benazepril in women with Hypertension as compared to genotype AA. 21449848 827807021
AGTR1 rs5186 A quinapril efficacy no This SNP was presented as AT1R A1166C. There was no significant relationship between this SNP and restenosis after percutaneous coronary intervention. Allele A is not associated with increased response to quinapril in people with Coronary Artery Disease as compared to allele C. 11849656 982048008
AGTR1 rs5186 AA nitrendipine efficacy yes Patients homozygous for the A allele had a greater reduction in pulse wave velocity as compared to patients carrying the C allele. No difference was seen in reduction of blood pressure between genotypes. Genotype AA is associated with increased response to nitrendipine in people with Hypertension as compared to genotypes AC + CC. 8952600 1043858602
AGTR1 rs5186 CC losartan efficacy yes This study involves IV administered EXP3174, the active metabolite of losartan. Patients with the CC genotype showed significantly blunted systemic and renal hemodynamic effects of AT1R blockade as compared to patients with the AA genotype. No patients with the AC genotype were studied. Genotype CC is associated with decreased response to losartan in people with Essential hypertension as compared to genotype AA. 15775779 1151429461
AGTR1 rs5186 AA perindopril efficacy yes Patients carrying the C allele had larger decreases in blood pressure, and had a greater reduction in pulse wave velocity as compared to patients homozygous for the A allele. Genotype AA is associated with decreased response to perindopril in people with Hypertension as compared to genotypes AC + CC. 8952600 1043858597
AGTR1 rs5186 AA losartan efficacy yes Cirrhotiç patients with portal hypertension and the AA genotype showed a higher decrease of hepatic venous pressure gradient as compared to patients carrying the C allele. Genotype AA is associated with increased response to losartan in people with Liver Cirrhosis as compared to genotypes AC + CC. 15743363 1144135755
AGTR1 rs5186 AC candesartan efficacy yes Subjects with the AC genotype had a greater decrease in N-terminal proB-type natriuretic peptide (NT-proBNP) over 6 months of treatment, as compared to AA homozygotes. Genotype AC is associated with increased response to candesartan in people with Heart Failure as compared to genotype AA. 18594050 982037728
AGTR1 rs5186 AA angiotensin II efficacy yes When infused with synthetic angiotensin II, subjects with the AA genotype exhibited a significant decrease in GFR as compared to subjects carrying the C allele, whose GFRs remained constant throughout infusion. No other differences were seen between genotype groups during infusion with angiotensin II. Genotype AA is associated with increased response to angiotensin II in healthy individuals as compared to genotypes AC + CC. 10594793 1183491853
AGTR1 rs5186 AA candesartan efficacy yes Homozygotes for the A allele had a greater decrease in systolic and diastolic blood pressure following 2 weeks of treatment, as compared to subjects with the AC genotype. Genotype AA is associated with increased response to candesartan in people with Heart Failure as compared to genotype AC. 18594050 982037714
AGTR1 rs5186 AC + CC captopril efficacy yes 99mTc-MAG3 clearance (MAG3cle) values were higher in patients who were carriers for the C allele, as compared to AA homozygotes, after treatment with captopril. MAG3cle provides an estimation of effective renal plasma flow (ERPF), and therefore of responsiveness to captopril treatment. Genotypes AC + CC are associated with increased response to captopril in people with Diabetes Mellitus, Type 2 as compared to genotype AA. 19286758 982044541
AGTR1 rs5186 AC candesartan efficacy yes No significant difference in the change of high sensitivity C-reactive protein (hsCRP) between genotypes was seen over 6 months of treatment. Genotype AC is not associated with response to candesartan in people with Heart Failure as compared to genotype AA. 18594050 982037742
AGTR1 rs5182 CC + CT perindopril efficacy yes Three SNPS are combined for a risk score ranging between 0 and 6: rs275651, rs5182, and rs12050217. Patients with risk scores of 0 and 1 and treated with perindopril had absolute risk reductions of 7.50% (95% CI: 3.69-11.73) and 4.30% (95% CI: 2.00-6.53), respectively. Nonsignificant estimated absolute risk increase of 1.32% was observed in patients with a PGXscore >=3. Lower risk score had better response to treatment by primary endpoint of cardiovascular mortality, nonfatal MI, and resuscitated cardiac arrest. Part of PERGENE trial for cardiovascular outcomes. Genotypes CC + CT is associated with decreased response to perindopril in people with Coronary Artery Disease as compared to genotype TT. 27021566 1447964466
AGTR1 rs5186 AC + CC losartan efficacy yes Subjects carrying the C allele had significantly higher glomerular filtration rate (GFR), decreased mean arterial pressure (MAP), and decreased aldosterone levels when treated with losartan as compared to subjects with the AA genotype. No significant differences in renal plasma flow (ERPF), renal blood flow (RBF), filtration fraction (FF), renal vascular resistance (RVR), and urinary sodium excretion (UnaV) were seen between genotype groups. Genotypes AC + CC are associated with increased response to losartan in healthy individuals as compared to genotype AA. 10594793 1043880431
AGTR1 rs5186 AC atorvastatin metabolism/PK yes AUC (0-time t) and AUC (0-infinity) values were significantly higher in the AC genotype (186.44±92.45 and 204.55±94.76 ng/ml/h, respectively) vs the CC genotype (95.57±43.10 and 109.28±40.84 ng/ml/h) (P<0.05 each) as well as when compared to AA + CC genotypes combined (159.28±79.71 ng/ml/h) (P<0.05). Clearance was significantly lower in the AC genotype (473.67±220.44 l/h) vs CC (810.19±275.81 l/h) or vs. AA+CC (614.68±277.11 l/h) (P<0.05). Genotype was not associated with half-life, Cmax, or elimination rate constant of atorvastatin. Genotype AC is associated with increased exposure to atorvastatin in healthy individuals as compared to genotypes AA + CC. 29250329 1449169568
AGTR1 rs275651 AA + AT perindopril efficacy yes Three SNPS are combined for a risk score ranging between 0 and 6: rs275651, rs5182, and rs12050217. Patients with risk scores of 0 and 1 and treated with perindopril had absolute risk reductions of 7.50% (95% CI: 3.69-11.73) and 4.30% (95% CI: 2.00-6.53), respectively. Nonsignificant estimated absolute risk increase of 1.32% was observed in patients with a PGXscore >=3. Lower risk score had better response to treatment by primary endpoint of cardiovascular mortality, nonfatal MI, and resuscitated cardiac arrest. Part of PERGENE trial for cardiovascular outcomes. Genotypes AA + AT is associated with decreased response to perindopril in people with Coronary Artery Disease as compared to genotype TT. 27021566 1447964381